Abecma (idecabtagene vicleucel) / BMS - LARVOL DELTA

Phase II Trial of Fixed-Duration Consolidation With Elranatamab Post-Idecabtagene Vicleucel CAR-T (EPIC) to Deepen Responses and MRD-Negativity in Relapsed or Refractory Multiple Myeloma (IMS 2026) - P2 | "Fixed-duration consolidation after ide-cel with Elra led to deepening of disease responses and MRD-conversion with ongoing, durable responses observed. The EPIC trial is fully accrued and updated data will be presented."

CAR T-Cell Therapy • Minimal residual disease • P2 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia

Mezigdomide (CC-92480) Following Idecabtagene Vicleucel (Ide-Cel) in Relapsed/Refractory Multiple Myeloma Is Safe and Leads to Deepening of Responses (IMS 2026) - "This study is the first demonstrating that sequential mezigdomide following ide-cel is feasible. Mezigdomide is safe in the post CAR-T setting and shows preliminary efficacy in patients who have residual myeloma, supporting the hypothesis that mezigdomide augments CAR-T cell response via enhanced residual CAR-T efficacy and/or direct CELMoD anti-myeloma activity."

Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia

Incidence of Parkinsonism and Non-ICANS Neurotoxicity With BCMA-Targeting Bispecific Antibodies vs CAR T-Cell Therapy in Multiple Myeloma: A Systematic Review and Meta-Analysis (SOHO 2026) - "BCMA-targeting bispecific antibodies (BsAbs)—teclistamab, elranatamab, linvoseltamab, pavurutamab—also redirect T cells to BCMA, yet the incidence of parkinsonism with these agents has not been systematically characterized...FAERS analysis (2832 events across teclistamab, talquetamab, elranatamab) identified non-ICANS neurotoxicity (41 events) and peripheral neuropathy (46 events) but no parkinsonism signal... Parkinsonism and MNT are established complications of BCMA CAR-T, particularly cilta-cel, likely reflecting sustained T-cell expansion. Parkinsonism has not been identified with BCMA BsAbs in clinical trials or pharmacovigilance data, possibly due to lower magnitude and shorter duration of T-cell activation. However, systematic underreporting and limited follow-up may obscure the true incidence."

Bispecific • CAR T-Cell Therapy • IO biomarker • Retrospective data • Review • Hematological Malignancies • Multiple Myeloma • Oncology

Hepatobiliary Adverse Event Signals Across FDA-Approved CAR-T Cell Therapy Agents: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (ACG 2026) - "Six agents were analyzed: axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, brexucabtagene autoleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel, by both generic and proprietary names from respective FDA approval dates. Of 22,486 CAR-T-related adverse event reports, 466 (2.1%) involved hepatobiliary adverse events; all met seriousness criteria (100%), with overall CFR 36.7% (171/466). Tisagenlecleucel had a positive signal (ROR 2.45; 95% CI 2.01-2.97; PRR 2.39; chi-square 69.53; CFR 51.3%), exceeding ciltacabtagene autoleucel (ROR 0.33; Z=10.60, p< 0.001) and brexucabtagene autoleucel (ROR 0.79; Z=5.49, p< 0.001). CD19-targeted agents showed higher disproportionality than BCMA-targeted agents (ROR 2.26; 1.75-2.91; p< 0.001)."

Adverse events • CAR T-Cell Therapy • Hematological Malignancies • Hepatology • Liver Failure

Incidence and Mortality of Immune Effector Cell-Associated Enterocolitis After CAR-T Cell Therapy: A Systematic Review and Meta-Analysis (ACG 2026) - "Among 68 patients treated with idecabtagene vicleucel, zero IEC-EC events occurred; the between-product difference was significant (Q=6.97, p=0.008). : Nineteen studies met eligibility criteria. Three studies provided full-cohort denominators for IEC-EC incidence after ciltacabtagene autoleucel (k=3, N=455, events=23). The pooled incidence was 4.92% (95% CI 3.05â7.16%; prediction interval [PI] 1.34â10.32%; I²=0%, Q p=0.43)."

CAR T-Cell Therapy • Retrospective data • Review • Gastrointestinal Disorder • Hematological Malignancies

Real-World Evaluation of Prophylactic Anakinra for Toxicity Mitigation in BCMA CAR-T Therapy (IMS 2026) - " This single-center retrospective study included multiple myeloma patients who received idecabtagene vicleucel (ide-cel) therapy...Tocilizumab and dexamethasone intervention was required in 6 (29%), and 8 (38%) patients, respectively... Prophylactic anakinra was well tolerated with a favorable safety profile in multiple myeloma patients receiving BCMA CAR-T therapy. Patients demonstrated manageable rates of severe CRS and ICANS, minimal infection risk, and adequate early cytopenia recovery. Early efficacy was preserved, suggesting anakinra prophylaxis may reduce toxicity without compromising outcomes."

CAR T-Cell Therapy • Clinical • HEOR • IO biomarker • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • IL6

Phase III Randomized Evidence for Bcma-Directed CAR T-Cell Therapy Versus Standard Regimens in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis (IMS 2026) - " Two phase III randomized trials met eligibility criteria: KarMMa-3 evaluating idecabtagene vicleucel versus investigator’s-choice standard regimens and CARTITUDE-4 evaluating ciltacabtagene autoleucel versus pomalidomide-based standard regimens, comprising 805 randomized patients overall. Published phase III randomized evidence demonstrates a substantial progression-free survival benefit for BCMA-directed CAR-T therapy compared with standard regimens in RRMM. These findings support earlier integration of BCMA-directed CAR-T therapy in appropriately selected patients with relapsed/refractory disease."

CAR T-Cell Therapy • P3 data • Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma

Outcomes of Anti-BCMA CAR-T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma and CNS Involvement Based on a Multicenter Real-World Study With Extended Follow-Up (IMS 2026) - "Here, we report real-world outcomes of commercially available anti-BCMA CAR T-cells (idecabtagene vicleucel (IC), ciltacabtagene autoleucel (CC)) in an extended follow-up of 25 patients (pts) with CNS-MM. BCMA-directed CAR T-cell therapy shows clinically meaningful activity with manageable toxicity profile in CNS-MM regardless of the specific CAR product. While outcomes remain inferior to those in non-CNS MM, our findings highlight the need for CNS remission during bridging therapy to optimize CAR-T outcome in this underrepresented subgroup of high-risk pts."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • CNS Disorders • Hematological Malignancies • Multiple Myeloma • Sarcoma • Solid Tumor

A CD4-Dominant, T-Helper-Skewed T Cell State Underlies Movement and Neurocognitive Toxicity After BCMA-Directed CAR-T Therapy in Multiple Myeloma (IMS 2026) - " We retrospectively analyzed 105 patients with relapsed/refractory multiple myeloma treated with cilta-cel (n=87) or ide-cel (n=18) at our institutions. Apheresis CD4/CD8 ratio >1.6 is an independent pre-infusion predictor of MNT. MNT+ patients showed greater CAR-T expansion, higher CD4 CAR+ cells, and CD4-dominant CSF infiltration. The T cell compartment showed helper-T-skewed programming in both CAR+ and bystander T cells, and elevated baseline inflammatory signaling."

CAR T-Cell Therapy • IO biomarker • Hematological Malignancies • Inflammation • Multiple Myeloma • CD4 • CD8 • IL2 • STAT5 • STAT5AWqe • TNFA

Individualized Holding and Bridging Therapy Achieves High Response Rates and Reduces Toxicity of Bcma-Directed CAR-T Cell Therapy in Multiple Myeloma (IMS 2026) - " In this single-center retrospective analysis, 88 consecutive RRMM patients received idecabtagene vicleucel (ide-cel; n=22) or ciltacabtagene autoleucel (cilta-cel; n=66). Adaptive, individualized holding and bridging therapy with a wide variety of treatment regimens achieved high pre-infusion response rates. Intensive chemotherapy as holding therapy did not compromise CAR-T product quality or manufacturing success. Deeper pre-infusion disease control was associated with significantly lower composite toxicity after BCMA-directed CAR-T therapy without severe neurotoxicity, positioning pre-infusion response as a potentially modifiable determinant of CAR-T-related toxicity."

CAR T-Cell Therapy • Clinical • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Multiple Myeloma • Rare Diseases

Impact of Immunomodulatory (Imid) Containing Holding Therapy (HT) Regimens on Outcomes in Relapsed/Refractory (RRMM) Patients Receiving Chimeric Antigen Receptor - T Cell (CAR-T) Therapy (IMS 2026) - " Of the 363 patients, 164 patients received ide-cel therapy and 199 patients received cilta-cel therapy. IMiD -based HT regimens did not demonstrate a statistically significant improvement in PFS for either ide -cel or cilta -cel although they did significantly improve OS in ide-cel patients. Rates of CAR-T associated toxicities were relatively similar , demonstrating that IMiD based regimens are relatively safe . However, IMiD based HT regimens do not improve CAR-T efficacy in the clinical environment despite demonstrating improvement in T-cell selection in vitro ."

CAR T-Cell Therapy • Clinical • Immunomodulating • Multiple Myeloma

Efficacy and Safety of Sequenced Bcma-Directed Therapies in Relapsed/Refractory Multiple Myeloma - a Retrospective, Multicenter, International Cohort Study (SEQ-BCMA Study) (IMS 2026) - "The four most frequent sequences were CAR T→bsAb (72, 40%), ADC→bsAb (29, 16%), CAR T→CAR T (ide cel→cilta cel, 26, 14%), and ADC→CAR T (25, 14%)...2 nd BCMA-Tx was not affected by the time between 1 st and 2 nd BCMA-Tx (6 mo; p=0.42) or intervening talquetamab (p=0.35)... Repeated BCMA-Tx yields high response rates with manageable toxicity, but PFS differs by sequence: CAR T→CAR T provides superior PFS compared to CAR T→bsAb but is attenuated after bsAb. ADC → CAR T appears less detrimental than bsAb→CAR T, though inferior to CAR T→CAR T. These data support CAR T before bsAb and highlight CAR T→bsAb as an unmet need."

Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia

Early Relapse Within 6 Months of Idecabtagene Vicleucel Predicts Poor Survival in Relapsed Refractory Multiple Myeloma (IMS 2026) - "In this large real-world cohort of patients treated with SOC ide-cel, relapse within ≤6 months was associated with particularly poor outcomes, with a median OS of less than a year. Notably, nearly half of patients with early relapses lacked conventional high-risk features, underscoring the limitations of current baseline risk stratification approaches."

Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

Comparison of Adverse Event (AE) Management Costs of Chimeric Antigen Receptor T-Cell (CAR T) Therapies in 4L+ Relapsed And/Or Refractory Multiple Myeloma (RRMM) (IMS 2026) - "The objective of this study was to model total per-patient AE management costs of anito-cel, cilta-cel, and ide-cel in 4L+ RRMM from a US health system perspective. In this analysis, anito-cel was associated with the lowest per-patient AE management costs compared with other CAR T therapies in 4L+ RRMM, driven by differences in incidence of high-cost AEs. Findings should be interpreted in the context of cost estimation assumptions and unadjusted cross-trial comparisons, which may also reflect evolving clinical and management practices over time. Overall, these findings highlight the importance of considering safety-related costs alongside clinical outcomes when evaluating CAR T therapies in RRMM."

Adverse events • CAR T-Cell Therapy • Acute Myelogenous Leukemia • CNS Disorders • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Movement Disorders • Multiple Myeloma • Myelodysplastic Syndrome • Parkinson's Disease

Clinical Trial Evidence Informing Efficacy and Safety of Fda-Approved Treatments in Relapsed and Refractory Multiple Myeloma (RRMM) for Patients (Pts) After Quadruple-Class Exposure (Qcex) (IMS 2026) - " QCEx RRMM subgroups from 8 single-arm trials were identified; 7 investigated 4 BCMA-targeting therapies (cilta-cel, CARTITUDE-2 [n=20]; ide-cel, KarMMa [n=28]; elranatamab, MagnestisMM-1/2/3/9 [n=87]; teclistamab, MajesTEC-1 [n=40]) and 1 investigated a GPRC5D bispecific antibody (BsAb; talquetamab, MonumenTAL-1 [n=75]). This SLR underscores the paucity of approved treatment options and the suboptimal clinical profiles of existing RRMM therapies for pts after QCEx. Anti-BCMA rechallenge was associated with diminished efficacy and high rates of G3-4 toxicity. Among agents evaluated, talquetamab demonstrated the highest response rates and greatest survival, supporting GPRC5D BsAb as a clinically meaningful therapeutic option in this population."

Clinical • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia

Clinical and Biological Predictors of Durable Response to Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - "Although idecabtagene vicleucel (ide-cel) is associated with lower response rates and shorter survival than ciltacabtagene autoleucel, a meaningful subset of patients achieves long-lasting responses. In this real-world multicenter cohort, ide-cel achieved durable disease control in 17% of heavily pre-treated RRMM patients. Durable response was independently predicted by three strata: functional status, cytogenetics, and systemic inflammation. Ferritin’s independence from ECOG suggests a distinct inflammatory mechanism, consistent with observed association between inflammation and impaired CAR-T efficacy."

Clinical • CNS Disorders • Hematological Malignancies • Inflammation • Movement Disorders • Multiple Myeloma • Parkinson's Disease

CIBMTR Real-World Outcomes of Older Patients Treated with Idecabtagene Vicleucel (IMS 2026) - "With extended follow-up, ide-cel effectiveness (ORR, PFS), as well as safety, was broadly comparable across age groups, albeit with numerically higher treatment-related mortality in older patients. Findings are directionally consistent with 6-mo outcomes reported for an earlier data cut and continue to highlight the benefit of ide-cel in older pts who may typically be overlooked for CAR T therapy."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

CIBMTR Real-World Outcomes of Frail Patients Treated with Idecabtagene Vicleucel (IMS 2026) - "With extended follow-up, ide-cel demonstrated comparable effectiveness and broadly similar safety, except for higher ICANS, in frail and non-frail pts, supporting its use across a wide RRMM population."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Multiple Myeloma • Respiratory Diseases

Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Primary Analysis of the Phase 2 "STEM" (Sequential T Cell-Engagement for Myeloma) Trial (IMS 2026) - P2 | " 27 pts (20M, 7F; median age 64; 21 White, 6 Black) enrolled, with median 4 (range 2-10) prior lines, 74% triple-class refractory, 11% prior BCMA therapy, and 11% prior talquetamab...93% received cilta-cel and 7% ide-cel... Cevo consolidation post-CAR T cells is feasible and well-tolerated in late-line RRMM, with 89% of pts showing sustained MRD-neg sCR at 1 year and promising 2-year PFS."

CAR T-Cell Therapy • Late-breaking abstract • P2 data • Cough • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Respiratory Diseases • Thrombocytopenia

Outcomes of Bispecific Antibody Rescue Therapy Following CAR-T Cell Therapy Failure in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis (SOHO 2026) - "Patients: Adults with RRMM progressing after commercial idecabtagene vicleucel or ciltacabtagene autoleucel; heavily pretreated (median, four to seven prior lines of therapy)...Interventions: BCMA-directed BsAbs (teclistamab, elranatamab; k = 4 studies) and GPRC5D/FcRH5-directed BsAbs (talquetamab, cevostamab; k = 2, descriptive only)... BsAbs demonstrate meaningful activity after BCMA-directed CAR-T failure in RRMM. GPRC5D-directed BsAbs showed numerically higher ORR (∼75%) than BCMA-directed BsAbs (∼49%), though this is based on descriptive data from two studies only and requires prospective validation. Substantial heterogeneity (I2 = 76.7%) highlights the influence of patient selection, BsAb target, and timing of initiation."

Bispecific • CAR T-Cell Therapy • Retrospective data • Review • Hematological Malignancies • Multiple Myeloma • Oncology

Redefining the Horizon: A Deep Survival Mixture Meta-Analysis Quantifying the Statistical Cure Fraction of Cellular Therapies in Relapsed Multiple Myeloma (SOHO 2026) - "Trials included ciltacabtagene autoleucel (cilta-cel; CARTITUDE-4, N = 208), idecabtagene vicleucel (ide-cel; KarMMa-3, N = 254), teclistamab (MajesTEC-1, N = 165), elranatamab (MagnetisMM-3, N = 123), talquetamab (MonumenTAL-1, N = 143), and cevostamab (phase 1/2, N = 160). Deep survival mixture modeling provides mathematically verifiable cure fraction estimates. CAR-T therapies possess a statistically significant cure fraction, whereas bispecific antibodies demonstrate almost nil cure probability despite similar initial response rates. This quantitative distinction resolves clinical sequencing debates: prioritize curative-intent CAR-T therapy first in eligible RRMM patients."

Retrospective data • Hematological Malignancies • Multiple Myeloma • Oncology

Efficacy and safety of ide-cel with lenalidomide (R) maintenance versus R maintenance alone in adult patients (pts) with NDMM who have suboptimal response to ASCT: phase 3 KarMMa-9 trial (IMW 2024) - P3 | "Not applicable"

Clinical • P3 data • Hematological Malignancies • Multiple Myeloma • Oncology

Phase II Multicenter Trial of Idecabtagene Vicleucel (Ide-cel) Followed By Lenalidomide Maintenance for Multiple Myeloma Patients with Sub-Optimal Response after an Upfront Autologous Hematopoietic Cell Transplantation: Top Line Results from the BMT CTN 1902 Clinical Trial (TCT-ASTCT-CIBMTR 2025) - "Pts received lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to ide-cel. Ide-cel led to high rate of CR and MRD-negativity in pts with <CR after standard first-line MM therapy including ASCT + maintenance. Ide-cel was safe in this setting with no high-grade CRS and no ICANS, and all patients were able to resume standard len maintenance"

Clinical • Late-breaking abstract • P2 data • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Oncology • Transplantation

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3 (ASH 2023) - P3 | "Introduction In the KarMMa-3 trial (NCT03651128), ide-cel, a BCMA-directed CAR T cell therapy (Tx), significantly improved median progression-free survival (13.3 vs 4.4 mo, HR 0.49, P < 0.001) and overall response rate (71% vs 42%, P < 0.001) vs std regimens in pts with RRMM who were TCE to immunomodulatory (IMiD®) agents, proteasome inhibitors (PIs), and daratumumab (Rodríguez-Otero NEJM 2023). No new safety concerns were identified for ide-cel; safety profile was consistent with previous reports. Study support 2seventy bio and Celgene, a Bristol-Myers Squibb Company."

Clinical • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology

Ide-cel versus Standard Regimens in Triple-class-Exposed RRMM: Phase 3 KarMMa-3 (EHA-EBMT-CART 2023) - P3 | "Patients were randomized 2:1 to receive ide-cel or a standard regimen (investigator choice of daratumumab/pomalidomide/dexamethasone, daratumumab/bortezomib/dexamethasone, ixazomib/lenalidomide/dexamethasone, carfilzomib/dexamethasone, or elotuzumab/pomalidomide/dexamethasone, based on prior regimen). Lymphodepletion with fludarabine and cyclophosphamide and optional bridging therapy preceded ide-cel infusion (target dose 150-450×106 CAR+ T cells; ≤540×106 cells allowed)... Ide-cel treatment resulted in a significant improvement in PFS and ORR, with deeper and more durable responses than standard regimens. Ide-cel benefit was consistent across difficult-to-treat subgroups. The toxicity profile of ide-cel was consistent with previous studies."

IO biomarker • P3 data • Hematological Malignancies • Immune Modulation • Infectious Disease • Inflammation • Multiple Myeloma • Oncology